Werewolf Therapeutics (NASDAQ:HOWL) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Werewolf Therapeutics reported a quarterly earnings per share of ($0.40), exceeding analysts' expectations of ($0.50) by $0.10.
• The company’s stock traded at $1.33, with a market capitalization of $59.68 million and a fifty-two week price range of $0.60 to $4.18.
• Institutional investors own approximately 64.84% of Werewolf Therapeutics shares, with significant increases in holdings from hedge funds during the second quarter.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10, Zacks reports.

Werewolf Therapeutics Stock Down 3.4%

Shares of Werewolf Therapeutics stock traded down $0.0450 during trading hours on Tuesday, hitting $1.2850. The company had a trading volume of 82,851 shares, compared to its average volume of 363,385. The company's 50-day moving average is $1.23 and its two-hundred day moving average is $1.14. Werewolf Therapeutics has a twelve month low of $0.5950 and a twelve month high of $4.18. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.09 and a quick ratio of 8.09. The company has a market cap of $58.76 million, a P/E ratio of -0.78 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, Wedbush reduced their price target on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $8.33.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently bought and sold shares of HOWL. Jane Street Group LLC bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Marshall Wace LLP bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $113,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Bridgeway Capital Management LLC increased its stake in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.